** Traws Pharma's TRAW.O shares soar 129% to $11.30 premarket
** TRAW says its experimental bird flu drug, tivoxavir marboxil, was safe and well-tolerated in early-stage trial
** A single dose maintained levels of the drug in the blood for over 23 days in the trial, co says
** Mid-stage trial is expected to begin in H1 2025, co says
** Bird flu has infected more than 860 dairy herds in 16 U.S. states since March and killed 123 million poultry since the outbreak began in 2022
** As of last close, stock has fallen 73.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.